Research Institute for Medicinal Plants and Herbs FAO Expert Roundtable BUDAPEST / Budakalasz 2012.04.2-5 Jozsef Peter PALLOS CEO RIMPH - PannonPharma.

Slides:



Advertisements
Similar presentations
Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.
Advertisements

JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
PIPELINE INFORMATION. Our mission is simple: make pharmaceutical information technology an asset for your business not a problem. We gather, analyze and.
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Cartagena Protocol on Biosafety -Reducing the Environmental Risks of Modern Biotechnology Secretariat of the Convention on Biological Diversity
DEVELOPMENT OF AN INNOVATION CENTER WIPO/INN/MCT/04/3 WIPO NATIONAL WORKSHOP ON INNOVATION SUPPORT SERVICES AND THEIR MANAGEMENT Muscat, April 20, 2004.
Ferring Controlled Therapeutics
Sustainable PruningThird Party AuditingQuality Assurance Patented Extraction Technologies Elite Plantation Sites ONE STEP IN THE FIGHT AGAINST CANCER ©
PLIVA, a Member of the Teva Group Tihomir Oreskovic
Clusters and Industrial Agglomerations Project GIFIP Survey in Serbia Novi Sad, 2008 by Isidora Budić, Massimo Iacovazzi.
EXIM Bank, NABARD, RRBs Group 4. Export Import Bank Of India (EXIM Bank of India)
Biopharmaceutical Quality
The Intellectual Property Rights Regime in India & US: The Evolving Landscape February 15, 2014, The Hyatt Regency Hotel, New Delhi D. CALAB GABRIEL.
From Field to Fork The S unripe Story Hasit Shah Managing Director Sunripe Kenya 23rd September 2009 Borschette Centre.
Master’s program in mathematics Eötvös University Budapest.
The survey of genetically modified foods on the Hungarian market, with method development and adaptation * Official Control of the Genetically Modified.
Bioprocess Pilot Facility
The Pharmaceutical Sector in Ireland SSDC Chemical Industry Plenary Meeting 9 th April 2013 Eurofound Dublin.
Exposure model for risk assessment and registration of amateur products in France 2013 Conference on Safe and Sustainable Use of Pesticides Bratislava–
Developing the Capacity of Nigerian IT Industry Presentation by Peter Jack, DG NITDA.
BACKGROUND: The Directorate General of Drug Administration under the Ministry of Health & Family Welfare, Government of the People's Republic of Bangladesh,
Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
CIPLA LTD Analyst Report By Siddharth Ghaisas. WHO IS CIPLA & WHAT DO THEY DO? WHO WHO - The Chemical, Industrial & Pharmaceutical Laboratories; - Founded.
Quality by Design: A Challenge to the Pharma Industry CAMP Member Companies March 2002 CAMP.
Pharmaceuticals Limited India – CIS International Pharma Conference 3-5 th March 2006, Mumbai Prashant Nagre Vice President – API Division.
MEDICINAL & AROMATIC PLANTS: A CHALLENGE FOR THE FUTURE IN AGRICULTURE Prof. Roberto DELLA LOGGIA Preside Facoltà Farmacia Università degli Studi di trieste.
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
1 Athens Alternative energy solutions in Israel: technology and business trends Dr. Ofer Alon, CEO, GEG - Green Energy Group Ltd. Joel Weill,
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Growth and Success through Partnering & Outsourcing.
The importance of standards and quality management. The detriments of sub- standard products on public health, safety and enterprise growth. Erick RAJAONARY.
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Zambia TRIPS workshop 3 Oct 2013.
 This project has been funded with support from the European Commission.
Association of Pharmaceutical Companies Representatives in Georgia APCRG, WASHINGTON DC, February
Trade segments, channels and structures for Natural Ingredients for Health Products Session 7 Centre for the Promotion of Imports from developing countries.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA. Presentation by: Dr. Joseph K. Yano B.Pharm (Nbi) L.L.B (Moi) Legal Officer Pharmacy and Poisons Board Ministry.
Györgyi Bela; Institute of Environmental Management, St. István University, Gödöllő, Hungary György Pataki; Institute of Environmental Management, St.
Biotech Inventions in Latin America Argentina Ignacio Sánchez Echagüe Marval, O’Farrell & Mairal.
Jennifer Orwa, PhD, OGW Chief Research Officer, Kenya Medical Research Institute, Center for Traditional Medicine and Drug Research Presentation at the.
BUDAPEST UNIVERSITY OF TECHNOLGY AND ECONOMICS Prof. Ákos Detrekői, DSc. Former Rector ( ) Barcelona, 10 September 2004.
Presented by Becky Cox Director, Pharmanex Marketing
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
DIETARY SUPPLEMENTS Dietary supplements are products that can be added to people’s diets. They include vitamins, minerals, herbs, and amino acids.
Janos Povazsan Rhone Vet Kft Brussels, 2nd December 2008.
Douglas Pharmaceuticals Ltd
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
By Georgi Boyanov BUS 449a: Change Management.  Statistics  History  Medicinal recipes  Vaccines  Innovation  Mergers & Acquisitions.
Lecture held on the Food Safety Conference March 2004 Dublin 1 Control Methods and Organisation of Official Controls in Hungary Dr. Peter A. BIACS,
Current Scenarios of Forage and Forage Seed Production and Use in Ethiopia Getnet Assefa November, 2015.
Nearly 70 licences have been issued to pharmaceutical enterprises in Georgia up to date. However, only about ten of them have real manufacturing facilities.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
1 CHALLENGES IN REGULATION OF TRADITIONAL AND ALTERNATIVE MEDICINES 24 th March, 2010 MOHSW Conference Room Registration of Herbal Drugs.
NUTRITION: HERBAL SUPPLEMENTS- EFFICACY & SAFETY by Dominique Hall Biology 1310 Professor Lang.
2016. Abdi Ibrahim Global Pharm LLP  Pharmaceutical plant for production of medicines in accordance with the GMP standards of the Republic of Kazakhstan.
INTRODUCTION A national drug policy is a document which covers all the areas and issues related to drugs. This document outlines all aspects of drugs.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
Indian API manufacturers are fit for outsourcing Pharma products
A Story of Two Countries Biotechnology Industry
GOOD MANUFACTURING PRACTICE FOR BIOPROCESS ENGINEERING (ERT 425)
Herbal Medicines.
Overview of vaccines prequalification
Sudan National Experience in TCM
LAVET Pharmaceuticals Ltd. Office: 2072 Zsámbék, Majális köz 1
LAVET Pharmaceuticals Ltd. Office: 2072 Zsámbék, Majális köz 1
Big Idea 1: A variety of factors led to the rise of industrial production.
What is Project’s Sustainability?
Herbal Plants.
THE HIGHLIGHTS OF DRUG REGULATION IN KENYA
Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.
Presentation transcript:

Research Institute for Medicinal Plants and Herbs FAO Expert Roundtable BUDAPEST / Budakalasz Jozsef Peter PALLOS CEO RIMPH - PannonPharma

RIMPH-PannonPharma  RIMPH member of the group of pharma companies:  PannonPharma Pharmaceuticals Ltd R+D, mid scale Manufacturing of solid dosage drugs  Trigon Biotech Ltd -  Clongen – Biopharma - Ltd  RIMPH - GYNKI vertically integrated company for medicinal plants to herbal medicines

>100 years of tradition >100 years of tradition  1884 Páter Béla the founder of medicinal plant research Kolozsvar  1915 Irk Károly established the HR Establishment for Medicinal Plants  1924 Kabay János started the poppy opiates extraction R+D  1925 Augustin Béla developped the medicinal plant improvement, and qualification system, as the model of the european medicinal plant regulations1951  1934 Békésy Miklós started thef claviceps purpurea R+D activities  1951 Institute for mMedicinal Plants - GyógynövényKutató Intézet  1957-től Tétényi Péter started new varieties, improvents > 50 officially tested end approved varieties  1969 Budakalasz site opening  1970 official medicinal plant state control activities, release of batches (plants, drugs, extracts etc) for medicinal use  1982 joint venture company of Hungarian (big )pharmaceutical companies  2003 Nature Conservation Area of Chemotaxonomy Botanical Garden

Janos Kabay (1896–1936) Invented the o pium free world Developped the Extraction process of alkaloids from poppy straw - first patent y1925 extraction from green plant - final patent y1931 extraction from dried poppy capsule - first pre INCB audit ever y1935 League of Nations -UN predecessor

World class researchers of RIMPH  Augustin Béla  Száhlender Károly  Kabay János  Kelp Ilona  Békésy Miklós  Kuntz János  Boros Ádám  Szathmáry Géza  Máthé Imre  Nyiredy Szabolcs  Dános Béla  Bernáth Jenő  Kiniczky Márta  Tyihák Ernő  Szatmáry Miklós  Máthé Imre jnr  Máthé Ákos

First ever medicinal plant state control system ( s) - y1922 Publishing of Guidelines for wild crfting, collection of medicinal plants „Útmutatás a vadontermő gyógynövények gyűjtésére” (Augustin-Darvas, Gyógy- és Ipari Növényforgalmi Iroda Kiadó Budapest, 1922, 199 pps.) -y1922 Publishing of Guidelines for cultivation of plant for medicinal and chemical use „Gyógy- és vegyipari növények termesztése” (Augustin-Darvas-Schneider, FM kiadás, Pátria Nyomda, Vác, 1922, 176 pps.) FM kiadás, Pátria Nyomda, Vác, 1922, 176 pps.) - y1923 control and use of state seal in export release - y1934 extension of control to field activities (cultivation, crafting, processing on site) This system was kept in force until years of 90s No control exists in recent years. No control exists in recent years.

RIMPH - GYNKI today as is RIMPH - GYNKI the vertically integrated company from medicinal plants research to finished products as herbal medicines involving: research, development, genebanking, varieties improvements, identification and QC analysis laboratories, extraction of APIs, manufacturing of finished pharmaceuticals, research, development, genebanking, varieties improvements, identification and QC analysis laboratories, extraction of APIs, manufacturing of finished pharmaceuticals, registration of own new products

Mission  Research on plants for medicinal use  New added value products  New varieties  New technologies in agriculture of MAPs  New API extraction technologies  11 new medicinal products 4 new varieties in pipeline

Herbal succes elements  New varieties (efficient, safe)  Motivated farmers  Skilled integrators  High tech processors  Market driven companies  Responsible authorities  Reasonable regulation  Supportive state admin

There are markets for sure - The y2050 vision - More people (?10 Bn) % / year market growth - example the poppy

Example -poppy alkaloids the growth is evident

Poppy the wonder chemical plant

Opium centuries are down

Morfin, Tebain are up

Morfin growth

Tebain growth

Aussi success story

Hungary lost markets